CD274 and non-small cell lung carcinoma: In the adjuvant, phase III IMpower010 trial, the subsequent addition of PD-L1 inhibitor, atezolizumab, to adjuvant platinum-based chemotherapy demonstrated a 34% disease-free survival advantage for patients with stage II-IIIA, PD-L1-positive NSCLC who underwent surgical resection [28].